New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
09:11 EDTIMS, SQBG, GLNG, BMY, BKS, CVRR, OMI, AERI, GIS, PXD, MDCI, NSPH, MONOn The Fly: Pre-market Movers
HIGHER: Barnes & Noble (BKS), up 7.7% after board authorizes management to separate Retail, Nook Media units... Monsanto (MON), up 5% after reporting better than expected Q3 results, raising its full year EPS outlook to the upper end of its previous guidance range and announcing a new $10B share repurchase authorization... IMS Health (IMS), up 7.7% after acquiring certain Cegedim businesses for $520M... Nanosphere (NSPH), up 16.2% after receiving 510(k) clearance for bacterial portion of Verigene EP test... Aerie Pharmaceuticals (AERI), up 37% after its trial of Roclatan achieved its primary efficacy endpoint... Medical Action (MDCI), up 94% after Owens & Minor (OMI) acquires the company for $13.80 per share in cash... Sequential Brands (SQBG), up 15% after acquiring Galaxy Brand for $100M cash, 13.75M shares... Pioneer Natural (PXD), up 2.3% after media reports that the company got U.S. permission to ship a type of light oil known as condensate... Bristol-Myers Squibb (BMY), up 2% after a Phase 3 study of nivolumab was halted early due to superior data. LOWER: General Mills (GIS), down 3.7% after Q4 earnings fall below analyst's consensus... Lindsay Corp. (LNN), down 5% after earnings miss, saying Iraq contract now more difficult to complete... Golar LNG (GLNG), down 2% after 11M share offering priced at $54 per share... CVR Refining (CVRR), down 7% after 6M share secondary offering of common units price at $26.07.
News For BKS;MON;GIS;BMY;NSPH;AERI;GLNG;MDCI;OMI;SQBG;PXD;CVRR;IMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
June 23, 2015
08:03 EDTSQBGMartha Stewart a great addition to Sequential Brands, says Brean Capital
Brean Capital said Martha Stewart (MSO) is a great addition to Sequential Brands' (SQBG) portfolio citing its brand awareness and the diversification of its platform. The firm believes many of its brands are in the early stages of organic growth and thus sees upside to the company's estimates. Brean Capital reiterated its Buy rating and raised its price target to $21 from $17 on Sequential Brands shares.
06:42 EDTMONMonsanto CEO: company not deterred by Syngenta rejections, WSJ reports
Subscribe for More Information
05:28 EDTMONSyngenta chairman reaffirms position regarding Monsanto proposal
Subscribe for More Information
June 22, 2015
17:16 EDTAERITPG Group lowers stake in Aerie Pharmaceuticals to 4.9% from 7.6%
13:20 EDTSQBGOn The Fly: Top stock stories at midday
Subscribe for More Information
11:59 EDTMONMonsanto June weekly volatility elevated into Q3 and outlook
Monsanto June weekly option implied volatility is at 39, July is at 22, October is at 22; compared to its 52-range of 14 to 27, suggesting large near term price movement into its expected release of Q3 results on June 24.
09:23 EDTSQBGMartha Stewart down 13.7% after Sequential Brands announces acquisition
Subscribe for More Information
09:20 EDTGISGeneral Mills Cereals to remove artificial flavors and colors
Subscribe for More Information
09:19 EDTSQBGSequential Brands signs definitive merger agreement to acquire Martha Stewart
Subscribe for More Information
09:17 EDTSQBGSequential Brands signs definitive merger agreement to acquire Martha Stewart
Subscribe for More Information
09:11 EDTSQBGSequential Brands trading halted, pending news
08:52 EDTBMYPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
05:35 EDTBMYAllied-Bristol Life Sciences licenses IP from Harvard University
Allied-Bristol Life Sciences, a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb, announced that it has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Malcolm Whitmanís lab at the Harvard School of Dental Medicine. Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Childrenís Hospital, Professor Whitmanís lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction response pathway. Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases. The licensing agreement with Harvardís Office of Technology Development is among the first in a series of discovery and development projects that Allied-Bristol Life Sciences intends to pursue. The license to the technology from Professor Whitmanís lab will be held by a new ABLS subsidiary specifically formed to pursue further research and pre-clinical development of the technology and associated molecules.
June 19, 2015
11:39 EDTBMYBristol-Myers announces European Commission approval of Opdivo
Subscribe for More Information
10:00 EDTAERIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Aerie Pharmaceuticals (AERI) upgraded to Buy from Hold at Canaccord... Amedisys (AMED) upgraded to Buy from Hold at Jefferies... Consolidated Edison (ED) upgraded to Hold from Sell at Evercore ISI... Delta Air Lines (DAL) upgraded to Outperform from Peer Perform at Wolfe Research... Deutsche Bank (DB) upgraded to Neutral from Underperform at Exane BNP Paribas... EP Energy (EPE) upgraded on better than expected well economics at SunTrust... Encana (ECA) upgraded to Outperform from Market Perform at BMO Capital... Energy Transfer Partners (ETP) upgraded to Buy at BofA/Merrill... Erickson (EAC) upgraded to Outperform from In-Line at Imperial Capital... Fiserv (FISV) upgraded on growth opportunities, margin outlook at Oppenheimer... IPC Healthcare (IPCM) upgraded to Buy from Hold at Jefferies... Mack-Cali Realty (CLI) upgraded on valuation at Stifel... Micron (MU) upgraded to Buy on sustainable margins and capex at Topeka... NuStar Energy (NS) upgraded to Buy from Neutral at BofA/Merrill... NuStar GP Holdings (NSH) upgraded to Buy from Neutral at BofA/Merrill... Ramco-Gershenson (RPT) upgraded to Outperform from Neutral at Baird... Retail Opportunity (ROIC) upgraded to Outperform from Market Perform at Raymond James... Royal Dutch Shell (RDS.A) upgraded to Outperform from Sector Perform at RBC Capital... Smith & Wesson (SWHC) upgraded to Outperform from Sector Perform at RBC Capital... Sovran Self Storage (SSS) upgraded to Buy from Hold at Cantor... Springleaf (LEAF) upgraded to Outperform from Neutral at Macquarie.
09:25 EDTSQBGSequential deal for Martha would be game changer, says Wunderlich
Subscribe for More Information
09:18 EDTAERIOn The Fly: Pre-market Movers
Subscribe for More Information
08:39 EDTMONMonsanto volatility elevated into Q3 and outlook
Monsanto June weekly option implied volatility is at 29, July and October is at 22; compared to its 52-range of 14 to 27, suggesting large near term price movement into its expected release of Q3 results on June 24.
08:25 EDTAERIAerie Pharmaceuticals upgraded to Buy, target raised to $40 at Canaccord
Subscribe for More Information
06:50 EDTAERIAerie Pharmaceuticals upgraded to Buy from Hold at Canaccord
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use